AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But ...
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab, to treat ...
Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...
ANAB Scope Extension Blosters Firm’s Auditing and Verification CapabilitiesDES MOINES, Iowa, Feb. 04, 2025 (GLOBE NEWSWIRE) - ...
Hosted on MSN7d
AnaptysBio initiated with an Outperform at Wolfe ResearchWolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...
EcoEngineers (Eco), a consulting, auditing, and advisory firm with an exclusive focus on the energy transition and ...
Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback